Experimental cell therapy takes on stubborn autoimmune diseases

NCT ID NCT07049081

Terminated Disease control Sponsor: Nanjing Legend Biotech Co. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals were to check safety and find the right dose, but the study was stopped early, so we have limited information.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LUCAR-G79 T cells (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for people with hard-to-treat autoimmune diseases like lupus.
What could go wrong: This was a very early, tiny study (only 3 people) that was terminated, so results are limited. Cell therapies can have serious side effects, and it's unclear if this approach will work for autoimmune conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease granulomatosis with polyangiitis idiopathic inflammatory myopathy immunoglobulin G4-related sclerosing disease systemic lupus erythematosus systemic sclerosis Takayasu arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY AUTOIMMUNE DISEASES

Contacts and locations

Locations

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China
The Third The People's Hospital of Bengbu

Bengbu, Anhui, China
The second Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.